Fixed-combination therapy to improve blood pressure control: experience with olmesartan-based therapy

Abstract

Effective treatment of high blood pressure represents a key strategy for reducing the burden of hypertension-related cardiovascular diseases. In spite of these well-established concepts, hypertension remains poorly controlled worldwide. In addition, treated hypertensive patients often remain at higher risk compared with the normotensive population, even when a satisfactory blood pressure control is achieved, owing to a high or very high added cardiovascular risk profile. An emerging strategy to improve blood pressure control in hypertensive patients is a more extensive use of combination therapy than monotherapy in the daily clinical practice. Within the possible antihypertensive drug combinations currently available for the clinical management of hypertension, those based on the association of drugs inhibiting the renin-angiotensin system and thiazide diuretics or calcium channel-blockers have demonstrated to be effective and safe in lowering both systolic and diastolic blood pressure levels with a good tolerability profile. This article provides an overview of fixed-combination strategies, with a particular focus on the fixed-combination strategies based on olmesartan medoxomil.

Single Polymer-drug Conjugate Carrying Two Drugs for Fixed-dose Codelivery

“…(4) Single polymer-drug conjugate carrying a combination of drugs: the formation of a chemically mixed micelle containing both types of drugs conjugated to a single polymer. The last two approaches are considered to be promising for fixeddose combination therapy purpose which can direct the system to be synergistic, additive or antagonistic [8,9]. For polymer-drug conjugate plus polymer-drug conjugate, the two populations of conjugates can be mixed in a given ratio to obtain micelles containing a determined ratio of two drugs.…”